Eliem Therapeutics is a company developing therapeutics intended to treat neuronal excitability disorders. It offers specialized research and development of drugs for the treatment of chronic pain, depression, epilepsy, and anxiety. The company progresses two clinical-stage assets with mechanisms of action for neurological diseases: ETX-810, an investigational chemical entity (NCE) for chronic pain; ETX-155, an investigational neuroactive steroid NCE that acts as a GABAA positive allosteric modulator (PAM).